Cyclopamine

目录号:S1146 别名: 11-deoxojervine

Cyclopamine Chemical Structure

Molecular Weight(MW): 411.62

Cyclopamine是一种特异性Hedgehog (Hh)信号通路拮抗剂,作用于Smoothened (Smo),在TM3Hh12细胞中IC50为46 nM。

规格 价格 库存 购买数量  
RMB 1227.56 现货
RMB 2188.93 现货
RMB 3037.37 现货
RMB 3833.48 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的4个实验数据:

  • (A) The effects of cyclopamine (10 μM) in pancreatic cancer cell invasion. The number of migrated cells was quantified by counting the number of cells from 10 random fields at 200 magnification. (B) The effects of cyclopamine on the expression of EMT-related molecules E-cadherin and vimentin, and Hh pathway-related proteins SMO and Gli-1 were analyzed by Western blotting following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor cyclopamine. Normal culture was used as a negative control. (C) The EMT-related molecules Ecadherin and vimentin mRNA levels, and Hh pathway-related genes at mRNA level were analyzed by real-time RT-PCR following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor Cyclopamine. Normal culture was used as a negative control.

    Cancer Lett 2012 322, 169-176. Cyclopamine purchased from Selleck.

    (A)[3H]thymidine incorporation assay of B16F10 melanoma cells treated with DMSO or cyclopamine after incubation with SA-CM from WT and Cav1KO dermal fibroblasts. Representative phase-contrast images of B16F10 cells treated with SA-CM from WT and Cav1KO fibroblasts with cyclopamine are shown on the right. Similar experiments (B) were done with A-375 cells incubated with SA-CM from hTBJ1-shCtrl and hTBJ1-shCAV1 cells.

    Cancer Res 2012 72, 2262-74. Cyclopamine purchased from Selleck.

  • (A) Exogenous Shh peptide (500 ng/mL) for 72 hours promoted expansion of CD34+ cells and CD34- cells, cyclopamine (10 μM) for 72 hours induced apoptosis of CD34+ cells and CD34- cells, as measured by 3-(3,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide (MTT) assay, n =4, bars, standard deviation. *Statistically significant compared with CD34+ cells. (B) Exogenous Shh peptide (500 ng/mL) promoted cell expansion after 48 hours and cyclopamine (10 μM) induced cell apoptosis within 24 hours measured by MTT assay (n=6).

    Exp Hematol 2012 40, 418-27. Cyclopamine purchased from Selleck.

    For MTT assays, cells (2,000 ~ 5,000 cells/well) were subcultured into 96-well plates according to their growth properties. Cell proliferation was assayed at 72 hr after treatment of Cyclopamine by adding 20 μl of 5 mg/ml 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution per 100 μl of growth medium. After incubating for 3-4 h at 37°C, the media were removed and 150 µl/well of MTT solvent (either absolute DMSO or isopropanol containing 4 mM HCl and 0.1% Nonidet-40) was added to dissolve the formazan. The absorbance of each well was measured by ELx808 (BioTek, Winooski, VT) or Wallac Victor2 (Perkin-Elmer Life Sciences, Boston, MA) Microplate Reader. Viable cells are presented as percent of control, vehicle-treated cells.

     

     

    Dr. Yong-Weon Yi from Georgetown University Medical Center. Cyclopamine purchased from Selleck.

产品安全说明书

Hedgehog/Smoothened抑制剂选择性比较

生物活性

产品描述 Cyclopamine是一种特异性Hedgehog (Hh)信号通路拮抗剂,作用于Smoothened (Smo),在TM3Hh12细胞中IC50为46 nM。
靶点
Smoothened [1]
(TM3Hh12 cells)
46 nM
体外研究

Cyclopamine 抑制Hedgehog信号通路, IC50 为46 nM, 且在[3H]Hh-Ag结合实验中,作用于CHO-K1细胞,抑制人类Smo受体活性,IC50为 280 nM。[1] Cyclopamine作用于表达Patched (PTCH) mRNA的肠源性肿瘤细胞,显著抑制 Hedgehog通路活性,这种作用存在剂量依赖性,且浓度为3 μM时,抑制肿瘤细胞生长,抑制达75-95%, 但是作用于不表达PTCH mRNA的结肠癌细胞没有效果,说明Cyclopamine 特定作用于Hedgehog 通路,且没有毒性。[2]通过与Smo直接作用而抑制Hedgehog信号,Cyclopamine (10 μM) 抑制SMOhigh Cyclopamine-反应细胞系L3.6sl和 Panc 05.04增殖,抑制达 75-80%,且使凋亡率提高2.5到 3.5倍,但是不影响BxPC3-SMOlow 细胞系。[3] Cyclopamine 处理E3LZ10.7细胞系,显著降低Snail mRNA,且提供E-钙粘着蛋白转录。Cyclopamine处理Hedgehog依赖型 L3.6pl 细胞,显著抑制浸润型细胞, 使转移细胞降低500多倍,但是对Hedgehog非依赖性细胞系Panc-1没有影响。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OS-RC-2 NWfFTZI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTVwOE[2OkDPxE1? MkLyV2FPT0WU
DOHH-2 MlqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPhTWM2OD17LkO1Olg6KM7:TR?= MonJV2FPT0WU
no-10 NVTHNVNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XVfWlEPTB;OT65NFM6KM7:TR?= NWSxNFB{W0GQR1XS
LS-513 M3HZXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfpTWM2OD1zMT6zOVQ4KM7:TR?= MWPTRW5ITVJ?
ALL-PO M4rjS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTFzLke3N|Qh|ryP NGO4UohUSU6JRWK=
8-MG-BA M{LKfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTF|LkGxNlMh|ryP NFi3VndUSU6JRWK=
RPMI-8402 M322cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDRSGdDUUN3ME2xOU45PTN5IN88US=> MojFV2FPT0WU
EoL-1-cell MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF[xcJNKSzVyPUG4MlU6PDhizszN NHjzfWNUSU6JRWK=
NALM-6 NI\LbolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfhOHNKSzVyPUG5MlAyPjdizszN NV7wN5N6W0GQR1XS
DEL M2jld2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTJyLkG0O|Eh|ryP MknDV2FPT0WU
SR NFGxbodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrjcGJKSzVyPUKzMlY4OTVizszN NGDJNWNUSU6JRWK=
697 Mn36S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTJd2hKSzVyPUK2MlYyPTVizszN NVnIcWJuW0GQR1XS
COLO-829 M{DPNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHyyT3lKSzVyPUK2Mlg1QDNizszN MXrTRW5ITVJ?
EVSA-T MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETOcXFKSzVyPUK3MlU2PjFizszN MV3TRW5ITVJ?
ATN-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTNzLkKzNlkh|ryP MWHTRW5ITVJ?
L-363 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTNzLke0OlEh|ryP M2LVdXNCVkeHUh?=
LAMA-84 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTN{LkWyNVEh|ryP NI\WW5dUSU6JRWK=
NOS-1 M3fJT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XPRWlEPTB;M{SuNlk2PiEQvF2= MlTZV2FPT0WU
BB30-HNC NEXIUW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PwXGlEPTB;M{SuN|MxPiEQvF2= NX;EeG83W0GQR1XS
BC-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTN5Lkm3OFYh|ryP NYTrSHlNW0GQR1XS
IST-SL2 M4jlSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrkeXpmUUN3ME2zPE4zOjRizszN MX;TRW5ITVJ?
D-392MG NEfwWo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXpPHFQUUN3ME20NE4zOjF3IN88US=> M3jiXHNCVkeHUh?=
no-11 MnrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PC[2lEPTB;NECuOVUzOSEQvF2= MkDLV2FPT0WU
LC4-1 Mk\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTRyLki3NVYh|ryP NInLT5lUSU6JRWK=
A388 NGnxUpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDqO2VKSzVyPUSyMlU5PDhizszN NWPKWI5RW0GQR1XS
NTERA-S-cl-D1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\DT3hKSzVyPUSyMlcxPzRizszN M{nxdHNCVkeHUh?=
CESS NV3BVFROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4GyVmlEPTB;NESuNlI{OiEQvF2= MWXTRW5ITVJ?
RS4-11 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\QRWM6UUN3ME20PU4xQTN6IN88US=> M4CwUnNCVkeHUh?=
MS-1 M3u3Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4P2V2lEPTB;NUCuPVM2OSEQvF2= NH;nU4tUSU6JRWK=
CTV-1 NWrVTFNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIf6c5ZKSzVyPUWxMlA4PCEQvF2= NF;DVplUSU6JRWK=
D-502MG NUXDWWlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;2VVhKSzVyPUWxMlYzPzFizszN NETOUYlUSU6JRWK=
ML-2 NXzoN5NHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4WzW2lEPTB;NUKuPVE6PSEQvF2= MmTkV2FPT0WU
SK-NEP-1 NHS2PG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\MN5hJUUN3ME21N{4{QTJ|IN88US=> M3TZT3NCVkeHUh?=
LOXIMVI NF;tW3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDuTWM2OD13Mz61PFg1KM7:TR?= NWfKeZRCW0GQR1XS
DJM-1 NUPLRnpXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTV4LkOzPVEh|ryP Mmj2V2FPT0WU
GI-1 NFLJR3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLUTWM2OD13Nj62NVQ6KM7:TR?= NXvjbFFqW0GQR1XS
IST-MES1 Mn[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fyPWlEPTB;NkCuOVQ6OyEQvF2= MkjzV2FPT0WU
MV-4-11 NIL3RodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTo[HVOUUN3ME22NE43PTN6IN88US=> M4\nOXNCVkeHUh?=
OVCAR-4 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XtdmlEPTB;NkOuOVY2PyEQvF2= NGXBSJJUSU6JRWK=
KE-37 NXXlVpM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTZ4LkK2Olgh|ryP NVrQVGd5W0GQR1XS
D-542MG M320NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLIUnJZUUN3ME22PE41OTN3IN88US=> MlK0V2FPT0WU
MHH-PREB-1 M1;LZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfpVFVKSzVyPUeyMlg1PDFizszN NIjv[YhUSU6JRWK=
MRK-nu-1 NXz1fHY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnX[XpKSzVyPUezMlQ4ODVizszN MnPsV2FPT0WU
D-247MG M3TzcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTwTWM2OD15Mz61OFQzKM7:TR?= MkH4V2FPT0WU
OCI-AML2 MmrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVeyZlIyUUN3ME23Ok46OzZ7IN88US=> NXHIfHk6W0GQR1XS
LP-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYq1TWZNUUN3ME24Nk45PzNzIN88US=> M13DSXNCVkeHUh?=
HCC1599 MmDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4[4eGlEPTB;OESuNlg{PyEQvF2= MWDTRW5ITVJ?
KARPAS-45 M4DBWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\5UWlEPTB;OESuOlk6OiEQvF2= MlPRV2FPT0WU
BE-13 M1\pfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TvTGlEPTB;OUmuNFQ4PyEQvF2= NEnmNFZUSU6JRWK=
GCIY NF:2OplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3NO4hVUUN3ME25PU4xQTV2IN88US=> MWjTRW5ITVJ?
BV-173 NX\QbFZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnZem9pUUN3ME2xNFAvOzJ3IN88US=> MljvV2FPT0WU
LB2518-MEL MlTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHi4SG1KSzVyPUGwNE44QDlizszN NFK4ZnpUSU6JRWK=
KS-1 M3\U[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvqTWM2OD1zMEGuOlM6KM7:TR?= M1G3UnNCVkeHUh?=
MOLT-16 M1rWc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvZSm9KSzVyPUGwOE46QDZizszN M1fnSnNCVkeHUh?=
NCI-H1770 NGXve21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPVTWM2OD1zMEiuO|g1KM7:TR?= NGPZUWRUSU6JRWK=
NCI-H82 NYPkRoc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zae2lEPTB;MUGwMlk4PiEQvF2= Mm\4V2FPT0WU
NCCIT NHjZdIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHDTWM2OD1zMUKuOVI6KM7:TR?= MnryV2FPT0WU
KALS-1 M4Hmfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fVXmlEPTB;MUG1Mlk1OSEQvF2= M3S2NHNCVkeHUh?=
LB2241-RCC MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTFzNj62O|kh|ryP NGfoPXNUSU6JRWK=
HH MnXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXGwT|N4UUN3ME2xNVcvOzl3IN88US=> Mon0V2FPT0WU
HD-MY-Z NFzjZYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWW1eWNuUUN3ME2xNVgvPDh6IN88US=> M3rYd3NCVkeHUh?=
EB-3 M3fzUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnGNFJKSzVyPUGyN{4xQTRizszN MnzDV2FPT0WU
BL-70 NUXOeZBQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLtTWM2OD1zMkOuNVI4KM7:TR?= MYLTRW5ITVJ?
K-562 NYDlcWNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7IZlRKSzVyPUGyOk4zPDVizszN MX;TRW5ITVJ?
HT-144 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXvTWM2OD1zM{OuNVY1KM7:TR?= NYPrO5VXW0GQR1XS
PF-382 MoS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTDbGxKSzVyPUGzOE4{PjFizszN MlHHV2FPT0WU
RPMI-8226 M{fvNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTF|NT6wOFUh|ryP MXzTRW5ITVJ?
NCI-H1355 MlnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTF|NT61PFch|ryP M4q0ZnNCVkeHUh?=
LXF-289 NFL4[JJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULOSFh3UUN3ME2xN|kvPzhzIN88US=> Mle2V2FPT0WU
NCI-H69 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLsTnZKSzVyPUG0Nk46OzJizszN MnfSV2FPT0WU
SK-MEL-1 M3fGTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PETmlEPTB;MUS3MlE{KM7:TR?= MWfTRW5ITVJ?
KARPAS-299 NEXCW2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXPTWM2OD1zNEmuNVIh|ryP M2rubnNCVkeHUh?=
GB-1 MmftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnVd|VKSzVyPUG0PU4{OjJizszN NY\sNlFqW0GQR1XS
CMK NYjxc4FnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTF2OT61NVUh|ryP MnzYV2FPT0WU
MPP-89 NEnPZYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fBbWlEPTB;MUW2MlA{PSEQvF2= M4f4bHNCVkeHUh?=
KU812 M3n0cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTF4MT65NFIh|ryP MXLTRW5ITVJ?
REH MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nXeWlEPTB;MU[yMlEzPSEQvF2= NITQToJUSU6JRWK=
NEC8 NYrxRZFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHX4VphKSzVyPUG2OU4xOjZizszN MVPTRW5ITVJ?
KP-N-YS NX\1XGtOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTmTWM2OD1zNkiuN|k2KM7:TR?= MVvTRW5ITVJ?
Ramos-2G6-4C10 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTF4OT65NVUh|ryP M1y5[XNCVkeHUh?=
Becker NHXwfHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nFe2lEPTB;MUe0MlE5KM7:TR?= NULSU2NSW0GQR1XS
LB647-SCLC MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\UUY9KSzVyPUG3OU45PDVizszN MVfTRW5ITVJ?
LU-139 MkPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2ewRmlEPTB;MUe4MlAyQSEQvF2= NWLTepdHW0GQR1XS
QIMR-WIL NX7XUm95T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTF5OT62OFYh|ryP M4DMOnNCVkeHUh?=
NCI-H1395 NGrS[YNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLiZlFKSzVyPUG3PU46QTZizszN M4jTb3NCVkeHUh?=
NOMO-1 M3XkR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnuWXJPUUN3ME2xPFIvQDVizszN MkPlV2FPT0WU
GI-ME-N NH63fFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrkTWM2OD1zOEeuPVY6KM7:TR?= NEHsR5dUSU6JRWK=
KMS-12-PE M2WwUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHZR3NPUUN3ME2xPFkvOjd|IN88US=> NXnUSndzW0GQR1XS
Daudi MkHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\kc2xGUUN3ME2xPVEvOTJ6IN88US=> MmXCV2FPT0WU
LB996-RCC Ml\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2THPWlEPTB;MUmxMlY6QSEQvF2= MmnsV2FPT0WU
NCI-H2107 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nFemlEPTB;MUmzMlc{QSEQvF2= NXXJTYVTW0GQR1XS
SK-PN-DW MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPkPFRjUUN3ME2xPVQvPzF7IN88US=> NYmzXFJjW0GQR1XS
MC-CAR MlK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\2bVl3UUN3ME2yNFIvOjV|IN88US=> MWLTRW5ITVJ?
SNB75 NEfaVmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTJ{MT65OEDPxE1? NFnxN|hUSU6JRWK=
ES4 NITrXXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTJ{Mz63PFMh|ryP NGDQWYdUSU6JRWK=
KARPAS-422 NX3HTVFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHSfYRKSzVyPUKyPE4{PTJizszN M{XmOXNCVkeHUh?=
NCI-H1648 MlHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;BTWM2OD1{MkmuOFg6KM7:TR?= MlHFV2FPT0WU
ES6 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTVd2FzUUN3ME2yN|kvPDNizszN MVjTRW5ITVJ?
KNS-81-FD NGjiXmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTJ2MT6xPVch|ryP NH3mT3dUSU6JRWK=
JAR Ml\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mof2TWM2OD1{NU[uNlI2KM7:TR?= MlXiV2FPT0WU
NB1 NHvXTmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPiTGZvUUN3ME2yOlAvPTF4IN88US=> MnPxV2FPT0WU
D-336MG M{DyO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDKTWM2OD1{NkCuOlk5KM7:TR?= MmroV2FPT0WU
BC-3 Mn\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWm5[4RFUUN3ME2yOlUvOTd6IN88US=> MULTRW5ITVJ?
HCC2218 MoHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEm3NGVKSzVyPUK2Ok41OTVizszN M3HJV3NCVkeHUh?=
TE-9 NYKyPJBoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmW4TWM2OD1{Nk[uOlI4KM7:TR?= MoDZV2FPT0WU
LB1047-RCC M2rDVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDoNWtwUUN3ME2yOlYvPzV|IN88US=> NUTxOJl7W0GQR1XS
CTB-1 NFz4OHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2C3WWlEPTB;Mk[5Mlk4OyEQvF2= M2W2VXNCVkeHUh?=
NB7 NGX0TJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnq2TWM2OD1{N{Gg{txO NF\NWndUSU6JRWK=
ST486 M3LUSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTJ5Nz60NVIh|ryP NUeyNplQW0GQR1XS
HCC1187 MnXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrFdFZ1UUN3ME2yPFIvQDFzIN88US=> MV;TRW5ITVJ?
NCI-SNU-16 NEnnPYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoW3TWM2OD1{OESuNlQ5KM7:TR?= NX7TfGdvW0GQR1XS
COR-L279 MkDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3YTWM2OD1{OUGuOVg1KM7:TR?= NEG3UlVUSU6JRWK=
ES8 M{DsT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjQbm86UUN3ME2yPVQvOTh{IN88US=> NYDhfXN6W0GQR1XS
U-698-M NYexWItYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLNTWM2OD1{OUiuNlQ{KM7:TR?= NIG5[4FUSU6JRWK=
HEL NVLxbJVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTNyOT6xOFkh|ryP M1\xVHNCVkeHUh?=
KINGS-1 NIq5bJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLvWHdKSzVyPUOxNE43PzRizszN NXLFdpZWW0GQR1XS
KY821 Mlf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTN|Nj61PVUh|ryP MX\TRW5ITVJ?
MZ1-PC MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTN2NT62NVgh|ryP NUTpTolNW0GQR1XS
LS-411N M4To[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnGwTWM2OD1|NUSuOlYh|ryP MmG4V2FPT0WU
SIG-M5 MmroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnNV3JKSzVyPUO1PU44QDJizszN M3XnXnNCVkeHUh?=
HT NEixcZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\GNpBOUUN3ME2zOlcvPzFzIN88US=> M{PCcnNCVkeHUh?=
HC-1 MoLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLSdo5uUUN3ME2zOlcvPzh5IN88US=> NWj2ZlFqW0GQR1XS
NCI-H1694 MmrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTN5Mj65N|Qh|ryP NWPyWIMzW0GQR1XS
BB65-RCC NFy4XHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLrTWM2OD1|N{[uNlQ2KM7:TR?= MliwV2FPT0WU
HAL-01 NFrFeIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlOzTWM2OD1|N{muPFM5KM7:TR?= NUnQbGI3W0GQR1XS
ARH-77 NYjyeItHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzscI9KSzVyPUO5OE4xODhizszN NXrQNoE5W0GQR1XS
MZ7-mel NIntfldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV34c2p7UUN3ME2zPVcvOjN|IN88US=> NEfEeWJUSU6JRWK=
SIMA NGi1XWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHy[plKSzVyPUSwN{46OzNizszN NH;zdXVUSU6JRWK=
DG-75 M3jZcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDJTWM2OD12MUWuOlk5KM7:TR?= NWruW2hYW0GQR1XS
HUTU-80 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTRzOT6xPFUh|ryP MmTQV2FPT0WU
KNS-42 NH3rPYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTR{NT64NVUh|ryP MlrOV2FPT0WU
SH-4 NUHYZ2JrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mke0TWM2OD12MkeuOVY2KM7:TR?= Mnf4V2FPT0WU
L-540 NYf1bHNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3aTWM2OD12M{GuNFMyKM7:TR?= M1TDXHNCVkeHUh?=
NB10 NYrsXGZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\FTWM2OD12NEGuNlM1KM7:TR?= NUW5TZl3W0GQR1XS
ES1 NWTvXWlbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnYWpd3UUN3ME20OVIvPzV|IN88US=> M3G2cHNCVkeHUh?=
KMOE-2 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXWOJdKSzVyPUS1Ok44OTFizszN NV;OWI9zW0GQR1XS
MC116 NEPMO2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXzWYVKSzVyPUS1PE4yOTZizszN M1jR[HNCVkeHUh?=
RCC10RGB NULMO4F2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{T1W2lEPTB;NE[wMlAxPSEQvF2= M1fwTnNCVkeHUh?=
RL95-2 M3HPeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfaTWM2OD12NkCuNlM4KM7:TR?= NVy2Ro5sW0GQR1XS
Raji NHXhOHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjjU5JqUUN3ME20OlgvOTR|IN88US=> M3qx[3NCVkeHUh?=
CAS-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHE[G9SUUN3ME20O|IvODd|IN88US=> MWXTRW5ITVJ?
Calu-6 M2GzVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjOXJE5UUN3ME20O|UvOjZ3IN88US=> NXXvU3BiW0GQR1XS
KG-1 NUTSPY44T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnZU|RnUUN3ME20O|gvPDRizszN MWLTRW5ITVJ?
LB771-HNC MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4njUGlEPTB;NEiyMlI{OiEQvF2= MnPMV2FPT0WU
ACN M{HDfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlm4TWM2OD12OUOuOVk6KM7:TR?= NXPlNYRDW0GQR1XS
KM12 M2HHZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHr5R5BKSzVyPUS5Ok42QDlizszN NF;L[|lUSU6JRWK=

... Click to View More Cell Line Experimental Data

体内研究 Cyclopamine 每天按50 mg/kg剂量处理小鼠,持续22天,消除HUCCT1移植瘤,且没有明显副作用。[2] Cyclopamine 按1.2 mg剂量处理Panc 05.04和 L3.6sl驱动的肿瘤7天,前者诱导明显的肿瘤细胞凋亡,后者降低肿瘤质量,降低达50-60%,但是作用于BxPC3-SMOlow肿瘤没有效果。[3] Cyclopamine单独处理E3LZ10.7 和L3.6pl移植瘤,显著抑制肿瘤转移,且和 Gemcitabine联用处理,完全废除转移。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
+ 展开

激酶实验:

Gli-Luc实验测定Hh 信号通路末期, 即使用荧光素酶进行读数,测定Gli的转录调控。Cyclopamine 在DMSO中连续稀释用于实验,然后加到空的实验板上。TM3Hh12 细胞(TM3 细胞含Hh反应受体基因结构 pTA-8xGli-Luc) 悬浮在含5% FBS 和15 mM Hepes pH 7.3的F12 Ham’s/DMEM (1:1)培养基上, 加到实验板上,与Cyclopamine在37oC下温育30分钟左右。1 nM Hh-Ag 1.5 加到实验板上,然后在37oC下温育。48小时后,在实验板中加入Bright-Glo或MTS,然后在492 nm处测定发光度或吸光度。通过分析反应曲线,使用R统计软件包测定IC50值。
细胞实验:[2]
+ 展开
  • Cell lines: SEG1, OE33, KYAE, KYSE180, SNU1, AGS, SNU16, NCI-N-87, HUCCT1, PANC1, PL5, PL6, BXPC3, HS766T, KYSE150, GBD1, DLD1, 和HCT116
  • Concentrations: 溶于DMSO, 终浓度为3 μM
  • Incubation Time: 4天
  • Method: 在96孔板上,用Cyclopamine 处理细胞。通过MTS实验测定细胞活力。进行CellTiter96比色测定,进行2和4天,然后在490 nm处通过测定光密度而测定存活细胞。
    (Only for Reference)
动物实验:[2]
+ 展开
  • Animal Models: 皮下注射HUCCT1细胞的无胸腺裸鼠
  • Formulation: 溶于DMSO, 然后用盐水稀释
  • Dosages: 50 mg/kg/day
  • Administration: 皮下注射处理
    (Only for Reference)

溶解度 (25°C)

体外 DMF 10 mg/mL warmed (24.29 mM)
Ethanol 2 mg/mL warmed (4.85 mM)
DMSO Insoluble
体内 从左到右依次加入纯溶剂:
10% DMSO+30% PEG 300+5% Tween 80+ddH2O
1mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 411.62
化学式

C27H41NO2

CAS号 4449-51-8
稳定性 powder
别名 11-deoxojervine

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    How to reconstitute the compound for in vivo use in mice?

  • 回答:

    One paper dissolved this drug in DMSO, and diluted in saline: Berman DM, et al. Nature, 2003, 425(6960), 846-851. Alternatively, you can try this vehicle: 10% DMSO+30% PEG 300+5% Tween 80+ddH2O for P.O. When preparing the solution, please dissolve the compound in DMSO clearly first. Then add PEG300 and Tween, after they mixed well, dilute with water.

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

相关Hedgehog/Smoothened产品

Tags: 购买Cyclopamine | Cyclopamine供应商 | 采购Cyclopamine | Cyclopamine价格 | Cyclopamine生产 | 订购Cyclopamine | Cyclopamine代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID